Samana Capital reported 6% passive stake in Onyx Pharmaceuticals Inc (ONXX) on October 24th. According to the filing, Samana Capital now possesses 3.84 million shares in ONXX. The firm’s previous position is unknown since its previous 13F filing is unavailable. ONXX had a strong path before the third quarter, and now it’s recovering from the slump in August. The stock has slightly lost 2% year to date, and is closed at $36 on October 27th.
ONXX was in seventeen hedge funds in the second quarter, based on Insider Monkey’s hedge fund tracking list. David E. Shaw’s D E Shaw had more than 3 million shares at that time. Roberto Mignone’s Bridger Management retained 1.1 million shares. Some ther famous hedge funds such as Ken Griffin’s Citadel Investment Group and Jim Simons’ Renaissance Technologies also reported small positions in ONXX.
Samana Capital is formerly known as Ziff Asset Management. The firm is located in New York City, NY.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company. According to Yahoo! Finance, the company “engages in the development and commercialization of therapies that target the molecular mechanisms causing cancer”. It also conducts clinical trials on Nexavar for the treatment of liver, kidney, non-small cell lung, thyroid, breast, ovarian, and colorectal cancers. As of December 31, 2010, Nexavar was approved in more than 90 countries worldwide for the treatment of unresectable liver cancer and advanced kidney cancer.